Halozyme Therapeutics (HALO) EBITDA (2010 - 2026)
Halozyme Therapeutics (HALO) EBITDA from Jun 30, 2010 to Mar 31, 2026. The TTM Halozyme Therapeutics (HALO) EBITDA is $525M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Halozyme Therapeutics (HALO) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -13.66% |
| 3 Years TTM | +27.38% |
| 5 Years TTM | +21.12% |
Annual EBITDA change of Halozyme Therapeutics (HALO)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $189M | -60.71% |
| 2025 | $480M | -14.48% |
| 2024 | $562M | +61.11% |
| 2023 | $349M | +27.24% |
| 2022 | $274M | -1.75% |
| 2021 | $279M | +89.03% |
| 2020 | $148M | -332.20% |
| 2019 | -$64M | -5.08% |
| 2018 | -$67M | -180.50% |
| 2017 | $83M | -202.92% |
| 2016 | -$81M | +213.54% |
| 2015 | -$26M | -57.94% |
| 2014 | -$61M | -22.65% |
| 2013 | -$79M | +50.73% |
| 2012 | -$53M | +180.42% |
| 2011 | -$19M | -64.47% |
| 2010 | -$53M | -7.47% |
| 2009 | -$57M | N/A |
Comparison Halozyme Therapeutics (HALO) five years EBITDA CAGR with competitors
Halozyme Therapeutics (HALO) five years EBITDA CAGR is 21.12%.